Cell-based Cancer Immunotherapy

1st Edition, Volume 183 - March 5, 2024
Editors: Abhishek Garg, Lorenzo Galluzzi
Language: English
Hardback ISBN:
9 7 8 - 0 - 4 4 3 - 1 3 9 9 5 - 6
eBook ISBN:
9 7 8 - 0 - 4 4 3 - 1 3 9 9 6 - 3

Cell-based Cancer Immunotherapy, Volume 183 provides the latest progress concerning research on anticancer cellular immunotherapies and their immunological, translation, or clinic… Read more

Purchase options

Limited Offer

Save 50% on book bundles

Immediately download your ebook while waiting for your print delivery. No promo code needed.

Institutional subscription on ScienceDirect

Request a sales quote

Cell-based Cancer Immunotherapy, Volume 183 provides the latest progress concerning research on anticancer cellular immunotherapies and their immunological, translation, or clinical aspects. Topics covered in this volume include Methods behind clinical DC vaccine products against glioblastoma, Fully closed and automated isolation of natural blood dendritic cells for cancer immunotherapy, Methods behind Oncolytic virus-based DC vaccines in cancer: towards a multiphase combined treatment strategy for Glioblastoma (GBM) patients, Identification of TCR repertoire patterns linked with anti-cancer immunotherapy, Training of epitope-TCR prediction models with healthy donor-derived cancer-specific T cells, Methods behind neoantigen predictions for anticancer vaccines, Methods behind CD137L-DC-EBV-VAX anticancer vaccine, and much more.

Additional sections cover Gold Standard Assessment of Immunogenic Cell Death Induced by Photodynamic Therapy: From In Vitro to Tumor Mouse Models and Anti-Cancer Vaccination Strategies, Methods behind TCR analyses for colorectal cancer-associated TILs, The use of xCELLigence, Incucyte, and/or Cr/LDH/maker-release assays, Humanized mouse models for anti-cancer therapy, In vitro re-challenge of CAR T cells, Methods behind adoptively transferred tumor draining lymphocytes for anticancer immunotherapy, and A murine glioblastoma platform to test cellular therapies with the standard of care.

Cover image
Title page
Table of Contents
Series Page
Copyright
Contributors
Chapter 1 Generation and quality control of mature monocyte-derived dendritic cells for immunotherapy
Abstract
1 Introduction
2 Materials
3 Methods
4 Notes
5 Concluding remarks
References
Chapter 2 Fully closed and automated enrichment of primary blood dendritic cells for cancer immunotherapy
Abstract
1 Introduction
2 Materials
3 Methods
4 Notes
5 Concluding remarks
References
Chapter 3 Methods behind oncolytic virus-based DC vaccines in cancer: Toward a multiphase combined treatment strategy for Glioblastoma (GBM) patients
Abstract
1 Introduction
2 Methods
3 Glioblastoma
4 Anticancer immunotherapy
5 The immune-editing in GBM
6 Dendritic cell vaccines as active specific immunotherapy for GBM
7 The changing landscape of immunotherapy of GBM
8 Integration of DC vaccination within the first-line combined treatment for GBM
9 Challenges to design randomized clinical trials with dendritic cell vaccines as part of first-line treatment of GBM
10 Immunogenic cell death immunotherapy for GBM
11 Extracellular microvesicles and apoptotic bodies: A new source of tumor antigens for DC vaccines?
12 Individualized multimodal immunotherapy as part of first-line multiphase combined treatment for GBM
13 IMI integrated during and after standard of care improves OS in adults with IDH1 wild-type GBM
14 Individualized multimodal immunotherapy in the current health care systems
15 The evidence
16 Quality of life
17 Perspectives
18 The model of multiphase combined treatment for patients with GBM
Acknowledgments
References
Chapter 4 Identification of TCR repertoire patterns linked with anti-cancer immunotherapy
Abstract
1 Introduction
2 Materials
3 Methods
Acknowledgments
References
Chapter 5 Training of epitope-TCR prediction models with healthy donor-derived cancer-specific T cells
Abstract
1 Introduction
2 Materials
3 Methods
4 Notes
5 Concluding remarks
References
Chapter 6 Methods behind neoantigen prediction for personalized anticancer vaccines
Abstract
1 Introduction
2 Materials
3 Methods
4 Concluding remarks
5 Addendum
References
Chapter 7 Methods for generating the CD137L-DC-EBV-VAX anti-cancer vaccine
Abstract
1 Introduction
2 Materials
3 Methods
4 Validation of CD137L-DC
5 Notes
6 Concluding remarks
Competing interests
References
Chapter 8 Gold standard assessment of immunogenic cell death induced by photodynamic therapy: From in vitro to tumor mouse models and anti-cancer vaccination strategies
Abstract
1 Introduction
2 Materials and step-by-step procedures
3 Concluding remarks
References
Chapter 9 Neoantigen identification: Technological advances and challenges
Abstract
1 Introduction
2 Targeting tumor-specific antigens (neoantigens)
3 Neoantigens identification methodologies
4 Challenges and future strategies
5 Conclusions
Conflicts of interest
References
Chapter 10 In vitro assays to evaluate CAR-T cell cytotoxicity
Abstract
1 Introduction
2 Overview of commonly used in vitro CAR-T cell cytotoxicity assays
3 Protocol for xCELLigence assay
References
Chapter 11 Humanized mouse models for anti-cancer therapy
Abstract
1 Introduction
2 Materials
3 Methods
Acknowledgments
References
Chapter 12 In vitro re-challenge of CAR T cells
Abstract
1 Introduction
2 Material
3 Methods
4 Concluding remarks
Acknowledgments
References
Chapter 13 Adoptive immunotherapy with cells from tumor-draining lymph nodes activated and expanded in vitro
Abstract
1 Introduction
2 Materials
3 Methods
4 Concluding remarks
References
Chapter 14 Toward more accurate preclinical glioblastoma modeling: Reverse translation of clinical standard of care in a glioblastoma mouse model
Abstract
1 Introduction
2 Materials
3 Methods
4 Concluding remarks
Conflicts of interest
References

Abhishek Garg

Prof. Abhishek D. Garg is currently Assistant Professor at Department of Cellular & Molecular Medicine (KU Leuven, Belgium) and head of the Laboratory for Cell Stress & Immunity also at KU Leuven. Dr. Garg did his post-doctoral training at KU Leuven, combined with research visitations at University of Helsinki, Finland, and De Duve Institute, Belgium, after receiving his PhD from KU Leuven. During his PhD-postdoc stints, Dr. Garg played an instrumental role in elucidating novel mechanisms that make cancer cell death immunogenic in the context of anticancer therapy. He worked on uncovering the links between endoplasmic reticulum stress, autophagy, apoptosis/necroptosis, and damage-associated molecular patterns (DAMPs) or danger signals in dying cancer cells. This work resulted in creation of innovative dendritic cell (DC) vaccines against glioblastoma.

His lab focuses on applying novel reverse translational approaches (i.e. human data to pre-clinical validation) to create innovative immunotherapy or biomarker solutions against hard-to-treat immunotherapy resistant tumors and eventually pave way for the forward translation of these solutions toward the clinic. His lab is working closely with oncologists (at home & abroad) for translation toward early-stage clinical trials.

His >100 publications have been cited >20,000 times (h-index >50). He has delivered >40 lectures at various (inter)national conferences or institutional/company seminars. Dr. Garg’s contributions have been recognized by the 41st Prix Galien award for Pharmacological Research (Belgium, 2023), KU Leuven Research Council Award (2016), European Society of Photobiology (ESP) Young Investigator Award (2013), and FWO-McKinsey & Company Scientific Prize (2012).

Lorenzo Galluzzi

Lorenzo Galluzzi is Assistant Professor of Cell Biology in Radiation Oncology at the Department of Radiation Oncology of the Weill Cornell Medical College, Honorary Assistant Professor Adjunct with the Department of Dermatology of the Yale School of Medicine, Honorary Associate Professor with the Faculty of Medicine of the University of Paris, and Faculty Member with the Graduate School of Biomedical Sciences and Biotechnology of the University of Ferrara, the Graduate School of Pharmacological Sciences of the University of Padova, and the Graduate School of Network Oncology and Precision Medicine of the University of Rome “La Sapienza”. Moreover, he is Associate Director of the European Academy for Tumor Immunology and Founding Member of the European Research Institute for Integrated Cellular Pathology. Galluzzi is best known for major experimental and conceptual contributions to the fields of cell death, autophagy, tumor metabolism and tumor immunology. He has published over 450 articles in international peer-reviewed journals and is the Editor-in-Chief of four journals: OncoImmunology (which he co-founded in 2011), International Review of Cell and Molecular Biology, Methods in Cell biology, and Molecular and Cellular Oncology (which he co-founded in 2013). Additionally, he serves as Founding Editor for Microbial Cell and Cell Stress, and Associate Editor for Cell Death and Disease, Pharmacological Research and iScience.

Affiliations and expertise

Assistant Professor of Cell Biology in Radiation Oncology, Department of Radiation Oncology, Weill Cornell Medical College, NY, USA

Life sciences

Physical sciences & Engineering

Social sciences & Humanities

Health